Statistics from Altmetric.com
A 59-year-old man with a history of intravenous drug use (DU) presented with a 3-day history of right-hand swelling, redness, warmth and pain. Physical examination was notable for a tensely oedematous hand with non-pitting oedema, warmth, blanching erythema and decreased range of motion (figure 1). He was empirically started on intravenous vancomycin for presumed skin and soft-tissue infection (SSTI). The patient was afebrile and studies including C reactive protein, leucocyte count and blood cultures were normal. An ultrasound study did not reveal any deep vein thrombosis. X-rays showed no fracture, foreign bodies or gas formation. There was no improvement after 48 hours of antibiotic therapy. MRI of the hand showed diffuse myositis of the intrinsic hand muscles and surrounding skin oedema (figures 2 and 3). Initially, he denied intravenous drug use into his arms, however, on further questioning, the patient admitted to injecting methamphetamine. Although he denied recent use, urine toxicology was positive for amphetamines. He had previously been taking buprenorphine through addiction clinic, but denied injecting it into his hands. Given the lack of serum inflammatory/infectious markers, lack of clinical improvement on antibiotics, the diagnosis of puffy hand syndrome was made. Oedema, erythema and pain improved after 48 hours of upper extremity elevation in a Murphy sling and resolved completely after 96 hours.
The differential diagnosis of the single swollen extremity includes SSTI (especially in patients with history of intravenous DU), osteomyelitis, deep vein thrombosis, arterial thrombosis and trauma. Puffy hand syndrome is a lesser-known complication of long-term intravenous DU and may affect about 7%–16% of intravenous drug users.1 It may present after periods of intermittent painless oedema which finally becomes permanent. Presentation may be delayed years after the reported last intravenous DU. Oedema is non-pitting, and typically affects the dorsal hand and fingers. Presentation may be complicated by superimposed infection.1 One study confirmed that injections in the hands were associated with puffy hand syndrome in intravenous DU.2 The pathophysiology of puffy hand syndrome is thought to involve venous and lymphatic insufficiency, as repeated injections result in sclerosis of veins and lymphatic vessels. The syndrome has especially been linked to buprenorphine injections. The diagnosis can be made clinically or with lymphoscintigraphy. Unfortunately, there are no specific treatments, however, some studies suggest the use of low-stretch bandages may help.3 In our case, the syndrome resolved after several days of elevation and compression bandage use.
In summary, while it is essential to rule out infection, deep vein thrombosis and other more common causes of a swollen extremity, our case highlights a lesser-known complication of intravenous DU. Although data are sparse on puffy hand syndrome, patients may benefit from traditional lymphoedema treatments including compression bandaging and garments, intermittent pneumatic compression, physical therapy and referral to specialists.
Common causes of a single swollen extremity includes skin and soft-tissue infection, trauma and deep vein thrombosis and must be considered especially in patients with history of intravenous drug use (DU), however, puffy hand syndrome is a lesser-known complication of intravenous DU that may present similarly.
Pathophysiology of puffy hand syndrome involves sclerosis and damage of veins and lymphatic vessels after repeated drug injections, leading to lymphoedema.
Although puffy hand syndrome has not been specifically studied, treatments such as compression bandaging, compression and physical therapy used for lymphoedema may be beneficial.
Patient consent for publication Obtained.
Contributors YA, JD and ES were all equally involved in the care of this patient as well as in the synthesis, drafting and editing of this manuscript.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.